does semaglutide affect your liver The FDA has granted accelerated approval for Wegovy (semaglutide 2.4 mg, once‑weekly) to treat metabolic dysfunction–associated steatohepatitis (MASH) in adults with moderate to advanced fibrosis (F2–F3) without cirrhosis. This is standout Focus on Semaglutide 2.4 mg/week

For patients with thyroid disease, particular attention should be paid to thyroid function monitoring, as weight changes may influence thyroid hormone requirements

This integrative approach provides 9-20 hours of weekly intervention in the form of individual, group, and sometimes family therapy together with other related support

Our team can help you understand the potential for coverage for applicable treatments

Above all, listen with respect

10 Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic 0.5 mg + basal insulin MET 10.7% with Ozempic 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 ADA=American Diabetes Association

Ditta produttrice Biomedica Foscama Group Smaltimento e raccolta differenziata Si consiglia di smaltire la confezione secondo le normative locali vigenti in materia di raccolta differenziata